OPM and Servier announce a strategic collaboration

OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment

Suresnes and Dijon (France), September 22, 2022, at 06:00pm – Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC – FR0011766229), announce a collaborative research agreement, named ‘STarT Pancreas’, to identify and validate new therapeutic targets in Pancreatic Ductal Adenocarcinoma (PDAC).

• Identification and validation of new therapeutic targets against pancreatic cancer
• Building a common Artificial Intelligence (AI) analytical platform
• Generation and sharing of clinical and biological data, AI tools and expertise in experimental pharmacology
• Servier may partner with OPM in a Drug Discovery program based on certain targets identified with this approach

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

More information: www.servier.com

Press contact:
Sonia Marques I presse@servier.com I Tel: +33 (0)1 55 72 40 21

About OncoSNIPE®

OncoSNIPE is a project that aims to develop and implement bioinformatics approaches using methodologies based on artificial intelligence, statistical learning and semantic enrichment, among others, to identify and characterize patients resistant to anti-cancer treatments and thus guide the research and development of specific therapeutic solutions through the identification of new targets. OncoSNIPE will enable Oncodesign Precision Medicine (OPM) to generate new therapeutic research avenues for its Experimentation and Discovery activities. The project is led and coordinated by Oncodesign through its subsidiary OPM; it brings together the skills of 4 industrial partners with complementary and synergistic expertise and core businesses: Expert AI (Paris), Coexya (Lyon), Acobiom (Montpellier) and Oncodesign (Dijon) and 12 academic institutions.
The OncoSNIPE program® aims to stratify and characterize patient populations resistant to cancer treatments. Oncodesign is collecting clinical, biological, genetic and imaging data and samples from chemo-naive patients with triple-negative breast cancer, pancreatic cancer and lung cancer during the course of their treatment in an observational clinical trial.

About OPM

Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign, is a technological company specialized in precision medicine. Its mission is to provide innovative therapeutic and diagnostic solutions to treat the phenomena of therapeutic resistance and metastatic evolution of cancers. The patient is at the heart of its thinking, its truly unique innovation model and its investments. With a diversified portfolio of compounds and therapeutic targets, OPM is positioned as a drug hunter of effective compounds against resistant and advanced cancers and other diseases without therapeutic solutions. For OPM, “working together is essential”, there can be no value creation without exchange and dialogue. For us, value creation results from reciprocity, i.e. balanced and equitable exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. More information: opm.oncodesign.com

Contact :
Philippe Genne | Chairman and Chief Executive Officer | Phone: +33 (0)3 80 78 82 60 | investisseurs@oncodesign.com